{
  "DOI": "10.1038/ejhg.2016.95",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/ejhg.2016.95",
  "alternative-id": [
    "BFejhg201695"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 1,
      "value": "12 August 2016"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "NH has received payments for consulting and speaker services from AstraZeneca and has attended advisory boards for AstraZeneca. She has also received grant support from AstraZeneca. MCJJ has declared no conflicts."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Hoogerbrugge",
      "given": "Nicoline",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Jongmans",
      "given": "Marjolijn CJ",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ],
    "date-time": "2016-08-12T08:50:59Z",
    "timestamp": 1470991859000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ],
    "date-time": "2023-05-18T17:17:57Z",
    "timestamp": 1684430277000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        10
      ]
    ],
    "date-time": "2024-04-10T11:58:24Z",
    "timestamp": 1712750304666
  },
  "is-referenced-by-count": 15,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "S1",
  "issued": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ]
  },
  "journal-issue": {
    "issue": "S1",
    "published-print": {
      "date-parts": [
        [
          2016,
          9
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2016,
            8,
            12
          ]
        ],
        "date-time": "2016-08-12T00:00:00Z",
        "timestamp": 1470960000000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/ejhg201695.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/ejhg201695",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/ejhg201695.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "S19-S26",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2016,
        9
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1200/JCO.2006.09.1066",
      "author": "S Chen",
      "doi-asserted-by": "publisher",
      "first-page": "1329",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR1",
      "unstructured": "Chen S, Parmigiani G : Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329–1333.",
      "volume": "25",
      "year": "2007"
    },
    {
      "DOI": "10.1093/jnci/djt095",
      "author": "N Mavaddat",
      "doi-asserted-by": "publisher",
      "first-page": "812",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg201695_CR2",
      "unstructured": "Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812–822.",
      "volume": "105",
      "year": "2013"
    },
    {
      "key": "BFejhg201695_CR3",
      "unstructured": "National Institute of Health and Care Excellence (NICE): Clinical guideline 164: familial breast cancer. Last update 2013. Available at \n                    www.nice.org.uk/guidance/cg164\n                    \n                   (accessed on 27 April 2015)."
    },
    {
      "key": "BFejhg201695_CR4",
      "unstructured": "Scottish Intercollegiate Guidelines Network (SIGN): SIGN Guideline No 135 Management of Epithelial Ovarian Cancer. Edinburgh: SIGN, 2013."
    },
    {
      "DOI": "10.1007/s12687-011-0042-4",
      "author": "D Gadzicki",
      "doi-asserted-by": "publisher",
      "first-page": "53",
      "journal-title": "J Community Genet",
      "key": "BFejhg201695_CR5",
      "unstructured": "Gadzicki D, Evans DG, Harris H et al: Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2: 53–69.",
      "volume": "2",
      "year": "2011"
    },
    {
      "author": "M Lambert",
      "first-page": "1505",
      "journal-title": "Am Fam Physician",
      "key": "BFejhg201695_CR6",
      "unstructured": "Lambert M : Guidelines for managing hereditary breast and ovarian cancer syndrome. Am Fam Physician 2009; 80: 1505–1507.",
      "volume": "80",
      "year": "2009"
    },
    {
      "DOI": "10.1200/JCO.2004.04.188",
      "author": "TR Rebbeck",
      "doi-asserted-by": "publisher",
      "first-page": "1055",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR7",
      "unstructured": "Rebbeck TR, Friebel T, Lynch HT et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055–1062.",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1093/jnci/djn442",
      "author": "TR Rebbeck",
      "doi-asserted-by": "publisher",
      "first-page": "80",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg201695_CR8",
      "unstructured": "Rebbeck TR, Kauff ND, Domchek SM : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80–87.",
      "volume": "101",
      "year": "2009"
    },
    {
      "DOI": "10.1200/JCO.2011.39.8545",
      "author": "K Alsop",
      "doi-asserted-by": "publisher",
      "first-page": "2654",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR9",
      "unstructured": "Alsop K, Fereday S, Meldrum C et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654–2663.",
      "volume": "30",
      "year": "2012"
    },
    {
      "DOI": "10.1200/JCO.2009.27.2997",
      "author": "BT Hennessy",
      "doi-asserted-by": "publisher",
      "first-page": "3570",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR10",
      "unstructured": "Hennessy BT, Timms KM, Carey MS et al: Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28: 3570–3576.",
      "volume": "28",
      "year": "2010"
    },
    {
      "author": "JM Lee",
      "first-page": "dju089",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg201695_CR11",
      "unstructured": "Lee JM, Hays JL, Annunziata CM et al: Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106: dju089.",
      "volume": "106",
      "year": "2014"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-13-2287",
      "author": "KP Pennington",
      "doi-asserted-by": "publisher",
      "first-page": "764",
      "journal-title": "Clin Cancer Res",
      "key": "BFejhg201695_CR12",
      "unstructured": "Pennington KP, Walsh T, Harrell MI et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764–775.",
      "volume": "20",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ejca.2004.09.008",
      "author": "T Rafnar",
      "doi-asserted-by": "publisher",
      "first-page": "2788",
      "journal-title": "Eur J Cancer",
      "key": "BFejhg201695_CR13",
      "unstructured": "Rafnar T, Benediktsdottir KR, Eldon BJ et al: BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 2004; 40: 2788–2793.",
      "volume": "40",
      "year": "2004"
    },
    {
      "DOI": "10.1038/sj.ejhg.5200652",
      "author": "L Sarantaus",
      "doi-asserted-by": "publisher",
      "first-page": "424",
      "journal-title": "Eur J Hum Genet",
      "key": "BFejhg201695_CR14",
      "unstructured": "Sarantaus L, Vahteristo P, Bloom E et al: BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001; 9: 424–430.",
      "volume": "9",
      "year": "2001"
    },
    {
      "DOI": "10.1056/NEJM199704173361602",
      "author": "JF Stratton",
      "doi-asserted-by": "publisher",
      "first-page": "1125",
      "journal-title": "N Engl J Med",
      "key": "BFejhg201695_CR15",
      "unstructured": "Stratton JF, Gayther SA, Russell P et al: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336: 1125–1130.",
      "volume": "336",
      "year": "1997"
    },
    {
      "DOI": "10.1002/humu.10090",
      "author": "H Yazici",
      "doi-asserted-by": "publisher",
      "first-page": "28",
      "journal-title": "Hum Mutat",
      "key": "BFejhg201695_CR16",
      "unstructured": "Yazici H, Glendon G, Yazici H et al: BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat 2002; 20: 28–34.",
      "volume": "20",
      "year": "2002"
    },
    {
      "key": "BFejhg201695_CR17",
      "unstructured": "Eccles D, Garcia EG, Balmaña J et al: Selecting Ovarian Cancer Patients for BRCA Mutation Testing: Findings from Guidelines and Literature Review. in Poster at the Conference of the British Society of Genetic Medicine (BSGM); 22–24 September 2014; Liverpool, UK."
    },
    {
      "DOI": "10.1093/annonc/mdr373",
      "author": "J Balmaña",
      "doi-asserted-by": "publisher",
      "first-page": "vi31",
      "journal-title": "Ann Oncol",
      "key": "BFejhg201695_CR18",
      "unstructured": "Balmaña J, Diez O, Rubio IT, Cardoso F : BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22: vi31–vi34.",
      "volume": "22",
      "year": "2011"
    },
    {
      "DOI": "10.6004/jnccn.2014.0127",
      "author": "MB Daly",
      "doi-asserted-by": "publisher",
      "first-page": "1326",
      "journal-title": "J Natl Compr Canc Netw",
      "key": "BFejhg201695_CR19",
      "unstructured": "Daly MB, Pilarski R, Axilbund JE et al: Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw 2014; 12: 1326–1338.",
      "volume": "12",
      "year": "2014"
    },
    {
      "DOI": "10.1186/s13073-015-0128-4",
      "author": "I Slade",
      "doi-asserted-by": "publisher",
      "first-page": "18",
      "journal-title": "Genome Med",
      "key": "BFejhg201695_CR20",
      "unstructured": "Slade I, Riddell D, Turnbull C, Hanson H, Rahman N : Development of cancer genetic services in the UK: A national consultation. Genome Med 2015; 7: 18.",
      "volume": "7",
      "year": "2015"
    },
    {
      "DOI": "10.1097/PPO.0b013e318238f579",
      "author": "KL Smith",
      "doi-asserted-by": "publisher",
      "first-page": "492",
      "journal-title": "Cancer J",
      "key": "BFejhg201695_CR21",
      "unstructured": "Smith KL, Isaacs C : BRCA mutation testing in determining breast cancer therapy. Cancer J 2011; 17: 492–499.",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1186/1897-4287-2-1-19",
      "author": "I van Oostrom",
      "doi-asserted-by": "publisher",
      "first-page": "19",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "BFejhg201695_CR22",
      "unstructured": "van Oostrom I, Tibben A : A counselling model for BRCA1/2 genetic susceptibility testing. Hered Cancer Clin Pract 2004; 2: 19–23.",
      "volume": "2",
      "year": "2004"
    },
    {
      "DOI": "10.1007/s10689-012-9524-8",
      "author": "HS Vig",
      "doi-asserted-by": "publisher",
      "first-page": "539",
      "journal-title": "Fam Cancer",
      "key": "BFejhg201695_CR23",
      "unstructured": "Vig HS, Wang C : The evolution of personalized cancer genetic counseling in the era of personalized medicine. Fam Cancer 2012; 11: 539–544.",
      "volume": "11",
      "year": "2012"
    },
    {
      "DOI": "10.1136/bmj.g1200",
      "author": "S Arie",
      "doi-asserted-by": "publisher",
      "first-page": "g1200",
      "journal-title": "BMJ",
      "key": "BFejhg201695_CR24",
      "unstructured": "Arie S : Routine testing for women with ovarian cancer. BMJ 2014; 348: g1200.",
      "volume": "348",
      "year": "2014"
    },
    {
      "DOI": "10.1136/jmedgenet-2012-100961",
      "author": "S Moghadasi",
      "doi-asserted-by": "publisher",
      "first-page": "74",
      "journal-title": "J Med Genet",
      "key": "BFejhg201695_CR25",
      "unstructured": "Moghadasi S, Hofland N, Wouts JN et al: Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling. J Med Genet 2013; 50: 74–79.",
      "volume": "50",
      "year": "2013"
    },
    {
      "DOI": "10.1111/codi.12880",
      "author": "N Dekker",
      "doi-asserted-by": "publisher",
      "first-page": "499",
      "journal-title": "Colorectal Dis",
      "key": "BFejhg201695_CR26",
      "unstructured": "Dekker N, Hermens RP, de Wilt JH, van Zelst-Stams WA, Hoogerbrugge N : Improving recognition and referral of patients with an increased familial risk of colorectal cancer: results from a randomised controlled trial. Colorectal Dis 2014; 17: 499–510.",
      "volume": "17",
      "year": "2014"
    },
    {
      "DOI": "10.1038/bjc.2012.599",
      "author": "A Brédart",
      "doi-asserted-by": "publisher",
      "first-page": "1012",
      "journal-title": "Br J Cancer",
      "key": "BFejhg201695_CR27",
      "unstructured": "Brédart A, Kop JL, Depauw A et al: Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. Br J Cancer 2013; 108: 1012–1020.",
      "volume": "108",
      "year": "2013"
    },
    {
      "DOI": "10.1037/a0014778",
      "author": "JG Hamilton",
      "doi-asserted-by": "publisher",
      "first-page": "510",
      "journal-title": "Health Psychol",
      "key": "BFejhg201695_CR28",
      "unstructured": "Hamilton JG, Lobel M, Moyer A : Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009; 28: 510–518.",
      "volume": "28",
      "year": "2009"
    },
    {
      "DOI": "10.1002/cncr.28879",
      "author": "AM Hirschberg",
      "doi-asserted-by": "publisher",
      "first-page": "341",
      "journal-title": "Cancer",
      "key": "BFejhg201695_CR29",
      "unstructured": "Hirschberg AM, Chan-Smutko G, Pirl WF : Psychiatric implications of cancer genetic testing. Cancer 2015; 121: 341–360.",
      "volume": "121",
      "year": "2015"
    },
    {
      "key": "BFejhg201695_CR30",
      "unstructured": "Bjorvatn C, Aas T, Fiane BE et al: BRCA mutation testing in all newly diagnosed patients with breast or ovarian cancer: the DNA BONus study. Abstract P12.016-M at the European Society of Human Genetics (ESHG); 31 May-3 June 2014; Milan, Italy."
    },
    {
      "DOI": "10.1200/JCO.2013.51.3226",
      "author": "MD Schwartz",
      "doi-asserted-by": "publisher",
      "first-page": "618",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR31",
      "unstructured": "Schwartz MD, Valdimarsdottir HB, Peshkin BN et al: Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 2014; 32: 618–626.",
      "volume": "32",
      "year": "2014"
    },
    {
      "author": "AS Sie",
      "first-page": "143",
      "journal-title": "Fam Cancer",
      "key": "BFejhg201695_CR32",
      "unstructured": "Sie AS, van Zelst-Stams WA, Spruijt L et al: More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer 2014; 13: 143–151.",
      "volume": "13",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2009.27.0660",
      "author": "ME Robson",
      "doi-asserted-by": "publisher",
      "first-page": "893",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR33",
      "unstructured": "Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K : American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28: 893–901.",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1093/annonc/mdu338.7",
      "author": "A George",
      "doi-asserted-by": "publisher",
      "first-page": "iv305",
      "journal-title": "Ann Oncol",
      "key": "BFejhg201695_CR34",
      "unstructured": "George A, Smith F, Cloke V et al: Implementation of routine BRCA gene testing of ovarian cancer (OC) patients at Royal Marsden Hospital. Ann Oncol 2014; 25: iv305–iv326.",
      "volume": "25",
      "year": "2014"
    },
    {
      "DOI": "10.1038/nature10166",
      "author": "Cancer Genome Atlas Research Network",
      "doi-asserted-by": "publisher",
      "first-page": "609",
      "journal-title": "Nature",
      "key": "BFejhg201695_CR35",
      "unstructured": "Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615.",
      "volume": "474",
      "year": "2011"
    },
    {
      "key": "#cr-split#-BFejhg201695_CR36.1",
      "unstructured": "5. NHS England. Clinical Commissioning Policy: Genetic Testing for BRCA1 and BRCA2 Mutations. October 2015"
    },
    {
      "key": "#cr-split#-BFejhg201695_CR36.2",
      "unstructured": "6. Available at   https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e01pb-brca-ovarian-canceroct15.pdf    ."
    },
    {
      "DOI": "10.1007/s10897-012-9519-5",
      "author": "S Salemink",
      "doi-asserted-by": "publisher",
      "first-page": "118",
      "journal-title": "J Genet Couns",
      "key": "BFejhg201695_CR37",
      "unstructured": "Salemink S, Dekker N, Kets CM, van der Looij E, van Zelst-Stams WA, Hoogerbrugge N : Focusing on patient needs and preferences may improve genetic counseling for colorectal cancer. J Genet Couns 2013; 22: 118–124.",
      "volume": "22",
      "year": "2013"
    },
    {
      "DOI": "10.1136/jmg.40.5.e56",
      "author": "EA Lobb",
      "doi-asserted-by": "publisher",
      "first-page": "e56",
      "journal-title": "J Med Genet",
      "key": "BFejhg201695_CR38",
      "unstructured": "Lobb EA, Butow PN, Meiser B et al: Women's preferences and consultants' communication of risk in consultations about familial breast cancer: impact on patient outcomes. J Med Genet 2003; 40: e56.",
      "volume": "40",
      "year": "2003"
    },
    {
      "DOI": "10.1200/JCO.1998.16.1.133",
      "author": "J Audrain",
      "doi-asserted-by": "publisher",
      "first-page": "133",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201695_CR39",
      "unstructured": "Audrain J, Rimer B, Cella D et al: Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol 1998; 16: 133–138.",
      "volume": "16",
      "year": "1998"
    }
  ],
  "reference-count": 40,
  "references-count": 40,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/ejhg201695"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Finding all BRCA pathogenic mutation carriers: best practice models"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "24"
}